Natera, Inc. (NTRA)
| Market Cap | 56.33B +126.6% |
| Revenue (ttm) | 2.71B +37.8% |
| Net Income | -192.35M |
| EPS | -1.37 |
| Shares Out | 144.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,690,565 |
| Open | 386.94 |
| Previous Close | 390.90 |
| Day's Range | 384.96 - 394.86 |
| 52-Week Range | 157.43 - 394.86 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 344.33 (-11.89%) |
| Est. Earnings | Nov 5, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $344.33, which is a decrease of -11.89% from the latest price.
News
Natera announces Signatera receives regulatory approval in Japan
Natera (NTRA) announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. Th...
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japa...
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Confe...
Natera Transcript: 2026 Global Healthcare Conference
Record revenue growth and strong operational leverage were driven by robust adoption of oncology and women's health products, with Signatera and Prospera achieving new milestones. International expansion, product innovation, and AI-driven efficiency support a positive long-term outlook.
Natera Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Q2 saw record growth and strong momentum in MRD adoption, with expanding biopharma partnerships and new product launches. Strategic investments in R&D, AI, and international markets are set to drive long-term growth, with significant opportunities in early cancer detection and rising ASPs.
Natera assumed with a Buy at UBS
UBS assumed coverage of Natera (NTRA) with a Buy rating and $435 price target Nateria is the leader in the large and growing MRD market, with additional support from its…
Natera initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn initiated coverage of Natera (NTRA) with a Buy rating and $385 price target Natera is the market leader in molecular residual disease testing with its Signatera…
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Natera announces publication of new data in Blood Neoplasia on Signatera
Natera (NTRA) announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory lympho...
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the pro...
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's l...
Natera and Angiex partner in tumor testing using Signatera
Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates, or ND-ADCs. Angiex is conducti...
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held ...
Natera to support new clinical trial assessing ctDNA dynamics with Latitude
Natera (NTRA) announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera’s Latitude tissue-free assay for molecular residual disea...
Natera price target raised to $363.50 from $249 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Natera (NTRA) to $363.50 from $249 and keeps an Overweight rating on the shares following quarterly results. The firm…
Natera price target raised to $360 from $290 at Guggenheim
Guggenheim raised the firm’s price target on Natera (NTRA) to $360 from $290 and keeps a Buy rating on the shares. The firm is updating its model to reflect Q2…
Natera price target raised to $350 from $305 at Stephens
Stephens raised the firm’s price target on Natera (NTRA) to $350 from $305 and keeps an Overweight rating on the shares. The firm is updating its model following the company’s…
Natera price target raised to $365 from $315 at Citi
Citi raised the firm’s price target on Natera (NTRA) to $365 from $315 and keeps a Buy rating on the shares post the Q2 report. The firm says Signatera continues…
Natera Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 saw record growth in all segments, with standout performance in organ health and oncology. Product innovation, robust clinical data, and expanded reimbursement are fueling momentum, while global expansion and major investments in lab capacity and early cancer detection position the business for sustained growth.
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored ...
Natera price target raised to $355 from $310 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Natera (NTRA) to $355 from $310 and keeps an Overweight rating on the shares.
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status
40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shar...
Natera price target raised to $340 from $325 at TD Cowen
TD Cowen raised the firm’s price target on Natera (NTRA) to $340 from $325 and keeps a Buy rating on the shares. The firm updated its model following Q2 results.
Natera price target raised to $360 from $300 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on Natera (NTRA) to $360 from $300 and keeps an Outperform rating on the shares.
Natera price target raised to $350 from $275 at RBC Capital
RBC Capital raised the firm’s price target on Natera (NTRA) to $350 from $275 and keeps an Outperform rating on the shares.